Factory 99% Cetrorelix Acetate Powder CAS 120287-85-6 Chemical Intermediate Cetrorelix Acetate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A669
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Cetrorelix Acetate
• CAS: 120287-85-6
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Cetrorelix Acetate
Appearance	White Powder
CAS NO.	120287-85-6
MF	C70H92ClN17O14
Storage	Keep in a cool, dry, dark location

 

Cetrorelix Acetate is a synthetic peptide drug that acts by competitively inhibiting the binding of endogenous to its receptors on pituitary gonadotrophs, thereby suppressing the secretion of LH and follicle-stimulating hormone (FSH).

 

1. Assisted Reproductive Technology (ART): Cetrorelix Acetate is commonly used in ART procedures to prevent premature ovulation in women undergoing controlled ovarian stimulation.
2. Cancer Treatment: It has been investigated for use in the treatment of certain cancers, such as ovarian and prostate cancer, where it may help to suppress hormone-driven growth of the tumor.
3. Hormonal Disorders: Cetrorelix Acetate is also used to manage hormonal disorders like benign prostatic hypertrophy and ovarian hyperstimulation syndrome.

1. Suppression of Hormone Secretion: By binding to receptors, Cetrorelix Acetate effectively suppresses the secretion of LH and FSH, thereby controlling ovarian stimulation and preventing premature ovulation.
2. Antitumor Activity: In cancer treatment, it may exhibit antitumor activity by reducing the levels of hormones that stimulate tumor growth.
3. Management of Hormonal Disorders: It helps to regulate hormone levels and alleviate symptoms associated with benign prostatic hypertrophy and ovarian hyperstimulation syndrome.